Mercer Global Advisors Inc Sage Therapeutics, Inc. Transaction History

Mercer Global Advisors Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$30.71 - $45.71 $369,502 - $549,982	-12,032 Closed	0 $0
Q4 2021 Feb 04, 2022	BUY	$37.06 - $47.11 $177,999 - $226,269	4,803 Added 66.44%	12,032 $512,000
Q3 2021 Nov 10, 2021	BUY	$40.26 - $57.37 $127,624 - $181,862	3,170 Added 78.1%	7,229 $320,000
Q2 2021 Aug 10, 2021	BUY	$54.88 - $79.29 $222,757 - $321,838	4,059 New	4,059 $231,000

220

52.7M

207K

191K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $730M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

Stay updated on Mercer Global Advisors Inc with notifications on news.